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Posttranslational modification of chromatin by
histone methylation has wide-ranging effects
on nuclear function, including transcriptional
regulation, maintenance of genome integrity,
and epigenetic inheritance. The enzymes uti-
lized to place histone methylation marks are
well characterized, but the identity of a histone
demethylation system remained elusive until
recently. The discovery of histone demethylase
enzymes capable of directly removing methyl
groups from modified lysine residues has
demonstrated that histone methylation is a dy-
namic modification. The most extensive family
of histone demethylase enzymes identified so
far contains a JmjC domain and catalyzes de-
methylation through a hydroxylation reaction.
Here, we identify PLU-1, a transcriptional re-
pressor implicated in breast cancer, as a histone
demethylase enzyme that has the ability to re-
verse the trimethyl H3K4 modification state.
Furthermore, we reveal that PLU-1-mediated
H3K4 demethylase activity plays an important
role in the proliferative capacity of breast cancer
cells through repression of tumor suppressor
genes, including BRCA1.
INTRODUCTION
Recent studies have demonstrated that covalent histone
modifications, particularly methylation, play important
roles in transcription regulation, genome integrity, and epi-
genetic inheritance (Martin and Zhang, 2005). Histone
methylation occurs on arginine and lysine residues and
causes no change in overall protein charge. Therefore,
methylation is thought to dictate functional outcome
though recruitment of effector proteins (Martin and Zhang,Molec2005). Most of the enzymes responsible for targeting ge-
nomic histone lysine methylation contain a SET domain
and are highly conserved from yeast to human. Specific
histone lysine methylation marks are commonly associ-
ated with either the active or the repressed state. For ex-
ample, histone H3K4, K36, and K79 methylation are gen-
erally associated with actively transcribed genes, whereas
H3K9, K27, and H4K20 methylation usually mark silenced
genes (Martin and Zhang, 2005). Recently, several con-
served protein domains have been identified that recog-
nize histone lysine methylation to elicit functional effects.
These include the chromodomain, PhD domain, WD40
repeat, and Tudor domain (Zhang, 2006). Methyl-lysine
recognition domains permit functional interpretation of
histone methylation marks as is exemplified by the tran-
scriptional repressor heterochromatin protein 1 (HP1),
which utilizes a chromodomain to bind chromatin contain-
ing H3K9 methylation and potentiate the repressed state
(Bannister et al., 2001; Lachner et al., 2001).
Until recently, histone methylation was considered
a static modification, but the identification of histone de-
methylase enzymes has revealed that this mark is dynam-
ically regulated (Shi et al., 2004; Tsukada et al., 2006). His-
tone demethylases have the capacity to regulate not only
the modification itself but also function indirectly to antag-
onize binding of effector proteins to modified chromatin.
This is exemplified by JHDM3A/JMJD2A, which can dis-
place HP1 from chromatin by removing the H3K9 methyl-
ation mark that HP1 recognizes (Cloos et al., 2006; Fodor
et al., 2006; Klose et al., 2006b). An extensive family of pro-
teins from yeast to human contain the JmjC domain, which
has recently been characterized as a histone demethylase
signature motif (Klose et al., 2006a). Thus far, the JmjC do-
main-containing family of enzymes has been shown to
catalyze removal of H3K9 and H3K36 methylation. There
are roughly 30 JmjC domain-containing proteins in mouse
and human, suggesting enzymes that target other methyl-
ation sites are likely to be found within this protein family.
The biological importance of the histone methylation
system in normal development and disease has become
more clear through functional analysis of enzymesular Cell 25, 801–812, March 23, 2007 ª2007 Elsevier Inc. 801
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PLU-1-Mediated H3K4 Demethylation in Breast CancerFigure 1. PLU-1 Is an H3K4 Demethylase
(A) Mammalian JARID1 family members are
highly similar in domain architecture and con-
tain JmjN, BRIGHT, JmjC, zf-C5HC2, and
PHD domains.
(B) The JmjC domain of JARID1 family mem-
bers is highly conserved within predicted
cofactor binding sites and exhibits extensive
similarity to the JHDM3A trimethyl H3K9/36
demethylase. The predicted Fe(II) binding resi-
dues are indicated by an asterisk (*) and the
a-ketoglutarate binding residues are indicated
by a number sign (#).
(C) Purified Flag-PLU-1 was incubated with
labeled histone substrates, and demethylase
activity analyzed by radioactive formaldehyde
release. Demethylase activity was observed
when PLU-1 was incubated with histone sub-
strates containing H3K4 methylated in the di-
and trimethyl modification states by a mutant
SET7 (Y245A), but not wild-type SET7 or any
other HMTs.
(D) PLU-1 dose-dependent release of radioac-
tive formaldehyde from demethylation reac-
tions.
(E) The H499Y mutation abrogated the PLU-1
demethylase activity. Empty vector and that
encoding wild-type or H499Y mutant PLU-1
were transfected into 293T cells. After immuno-
precipitation, equal amounts of recombinant
protein as assessed by western blot were
used in radioactive formaldehyde release as-
says as described in (C).
(F and G) Mass spectrometry analysis of PLU-1
activity toward H3K4me3 (F) and H3K4me2 (G)
peptide substrates. Both the mass spectra (left)
and quantification (right) of the demethylation
reactions are shown.involved in placing these modifications and detailed ex-
amination of genomic histone methylation profiles. For
example, genetic studies in fly and mouse indicate that
histone H3K27 methylation plays important roles in early
development through the regulation of HOX gene expres-
sion (Cao et al., 2002; Pasini et al., 2004; Ringrose and
Paro, 2004). In addition, analysis of histone modifications
in cancer has revealed that histone methylation and his-
tone methyltransferase enzymes contribute to the process
of malignancy (Fraga et al., 2005; Schneider et al., 2002;
Varambally et al., 2002). More recently, the JHDM3C/
GASC1 demethylase was shown to contribute to the
proliferative capacity of certain cancer cell lines, although
the contribution of histone demethylation to this process
remains to be examined (Cloos et al., 2006).
To identify additional histone demethylases, we have
utilized a bioinformatic approach to narrow down the
number of JmjC domain-containing proteins that are
potentially enzymatically active based on conservation
within the JmjC domain (Klose et al., 2006a). To identify
additional histone demethylase enzymes, we took a candi-
date approach within the seven subfamilies of the JmjC
domain-containing proteins. Here, we identify and char-802 Molecular Cell 25, 801–812, March 23, 2007 ª2007 Elseviacterize PLU-1, a JARID1 family member previously linked
to breast cancer (Lu et al., 1999), as an H3K4 demethy-
lase. PLU-1 and its associated H3K4 demethylase activity
play important roles in the proliferation of breast cancer
cells through direct transcriptional repression of tumor
suppressor genes that include BRCA1.
RESULTS
JARID1 Proteins Are Potential Histone
Demethylases
There are four JARID1 proteins in mouse and human:
RBP2 /JARID1A, PLU-1/JARID1B, SMCX/JARID1C, and
SMCY/JARID1D. All four JARID1 proteins contain at least
one JmjN, BRIGHT, PHD, JmjC, and C5HC2-zinc-finger
(ZF) domain (Figure 1A). Recently, the JmjC domain has
been shown to catalyze Fe(II)/a-KG-dependent hydroxyl-
ation reactions that lead to histone demethylation
(Tsukada et al., 2006). Bioinformatic analysis of the JmjC
domain in JARID1 proteins indicates that predicted Fe(II)
and a-ketoglutarate (a-KG) binding sites are conserved
(Figure 1B), suggesting that these proteins may consti-
tute functional hydroxylase enzymes. In addition, theer Inc.
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lation suggests these proteins are likely histone demethy-
lases. RBP2/JARID1A and PLU-1/JARID1B are the most
thoroughly characterized JARID1 family members, and
both have documented roles in cancer cell proliferation
(Benevolenskaya et al., 2005; Lu et al., 1999). Because
PLU-1 is abnormally expressed in breast cancer cell lines
and tissues (Barrett et al., 2002; Lu et al., 1999; Madsen
et al., 2002), we sought to examine whether PLU-1 is a his-
tone demethylase.
PLU-1/JARID1B Is an H3K4 Demethylase
To determine if PLU-1 is an active histone demethylase,
full-length Flag-tagged human PLU-1 was expressed in
SF9 cells and purified by affinity chromatography
(Figure S1 in the Supplemental Data available with this ar-
ticle online). To determine whether PLU-1 is an active his-
tone demethylase, recombinant PLU-1 was incubated
with histone substrates containing radioactively labeled
methyl groups corresponding to several characterized
methyl-lysine sites on histones H3 and H4 (Figure 1C). His-
tone demethylase activity was monitored by release of the
demethylation product formaldehyde. Release of labeled
formaldehyde was only observed in reactions containing
histone substrates labeled with a mutant SET7 (SET7
Y245A) (Figure 1C), which has the capacity to methylate
H3K4 to the di- and trimethyl states (Xiao et al., 2003).
Consistent with the notion that the enzymatic activity is in-
trinsic to PLU-1, a dose-dependent formaldehyde release
was observed on H3K4 substrates (Figure 1D). Further-
more, immunoprecipitation of transiently transfected
mutant PLU-1 with a change in the Fe(II) binding site
(H499Y) followed by enzymatic activity assays demon-
strated that the H499Y mutation abrogated PLU-1 deme-
thylase activity (Figure 1E).
Currently, lysine-specific histone demethylase 1 (LSD1)
is the only characterized enzyme capable of removing
H3K4 methylation (Shi et al., 2004). LSD1 differs mecha-
nistically from the JmjC domain-containing histone deme-
thylases, as its activity is limited to the me1 and me2 mod-
ification states due to the requirement of a protonated
nitrogen on the lysine amine group to initiate demethyla-
tion. The fact that LSD1 targets H3K4me1/me2 left open
the possibility that H3K4me3 was an irreversible modifica-
tion state. Given that PLU-1 does not target H3K4me1
containing substrates generated by SET7 (Figure 1C),
we sought to determine if PLU-1 had the capacity to re-
move H3K4me3. To this end, we incubated recombinant
PLU-1 with histone peptides corresponding to the N-
terminal tail of histone H3 containing me3, me2, or me1
modifications at the lysine four position. Mass spectro-
metric analysis demonstrates that PLU-1 is able to deme-
thylate both H3K4me3 and H3K4me2, but not H3K4me1
(Figures 1F, 1G, and data not shown). Interestingly, the
demethylation reaction does not appear to be processive,
as no H3K4me1 or H3K4me0 was generated when an
H3K4me3 peptide was used as a substrate. The above re-
sults collectively allow us to conclude that PLU-1 is anMolecH3K4-specific histone demethylase that can target re-
moval of the H3K4me3 modification state.
PLU-1 Targets H3K4 Demethylation In Vivo
To verify that PLU-1 also targets H3K4 demethylation in
vivo, PLU-1 was overexpressed in U2OS cells and histone
methylation was analyzed by using modification-specific
antibodies. Consistent with mass spectrometry analysis
demonstrating that PLU-1 is an H3K4me3 demethylase
(Figure 1F), overexpression of PLU-1 resulted in a clear
reduction of H3K4me3 staining (Figure 2A, top panels).
This effect is dependent on the PLU-1 demethylase activ-
ity, as overexpression of the enzymatic-defective H499Y
mutant has no noticeable effect on the H3K4me3 levels
(Figure 2A, bottom panels). In addition to H3K4me3, over-
expression of PLU-1 also resulted in a significant de-
crease on the H3K4me2 and me1 levels (Figures 2B and
2C). However, overexpression of PLU-1 had no effect on
the other histone methylation sites, including H3K27me3
(Figure 2D) and H3K9me3 (Figure 2E). It is interesting to
note that PLU-1 efficiently catalyzed removal of the
H3K4me1 in vivo (Figure 2C), although recombinant
PLU-1 can only demethylate H3K4me3 and H3K4me2
when analyzed in vitro (Figure 1). This observation sug-
gests that the ability of PLU-1 to demethylate H3K4me1
may rely on additional factors in vivo.
In addition to the JmjC domain, PLU-1 also contains
JmjN, BRIGHT, PHD, and C5HC2-ZF domains (Figure 1A).
Previous studies have revealed that domains in addition
to JmjC can significantly contribute to enzymatic activity
(Fodor et al., 2006; Klose et al., 2006b; Tsukada et al.,
2006; Yamane et al., 2006). To test whether other domains
within PLU-1 also contribute to demethylase activity, we
generated a series of deletion mutants (Figure 3A) and
monitored enzymatic activity by analyzing H3K4me3
levels in transfected cells. Removal of the C-terminal PHD
domains did not affect PLU-1 demethylase activity (Fig-
ure 3B). Further deletion of the C-terminal C5HC2-ZF
domain resulted in both nuclear and cytoplasmic localiza-
tion and caused a complete loss of demethylase activity
(Figure 3C). In JHDM3A/JMJD2A, the JmjN domain is
required for efficient enzyme function (Fodor et al., 2006;
Klose et al., 2006a). To examine whether PLU-1 also re-
quires the JmjN domain for enzymatic activity, the JmjN
domain was deleted within the context of the full-length
protein (Figure 3A). Although deletion of the JmjN domain
did not affect nuclear localization, it completely abrogated
H3K4 demethylase activity (Figure 3D). In PLU-1, the JmjN
and JmjC are intervened by BRIGHT and PHD domains
(Figure 3A). Deletion of these domains had no effect on
PLU-1 nuclear localization but did result in loss of deme-
thylase activity (Figure 3E and F). Given that neither the
BRIGHT nor the PHD domains are absolutely required
for demethylase activity in other JmjC domain-containing
proteins, deletion of these intervening domains may alter
the spatial arrangement between the JmjN and JmjC
domains and thus inhibit accurate folding of the functional
enzyme.ular Cell 25, 801–812, March 23, 2007 ª2007 Elsevier Inc. 803
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PLU-1-Mediated H3K4 Demethylation in Breast CancerFigure 2. PLU-1 Demethylates H3K4 In Vivo
PLU-1-MYC or a PLU-1-MYC with a mutation in the catalytic domain (H499Y) was overexpressed in U2OS cells, and histone modification levels were
analyzed by immunofluorescent staining with histone methylation site-specific antibodies. Cells expressing transfected PLU-1, indicated by arrows,
show a marked decrease in the levels of H3K4me3 ([A], top panels), H3K4me2 ([B], top panels), and H3K4me1 ([C], top panels). The effects on H3K4
methylation were specific for H3K4 (D and E) and were abrogated by expression of the H499Y mutant ([A], [B], and [C], bottom panels). Shown are
representative fields for each transfection.PLU-1 Contributes to MCF-7 Cell Proliferation
by Facilitating G1 Progression
PLU-1 was initially isolated as a transcript overexpressed
in human breast cancer cell lines, and analysis of its ex-
pression in breast cancer cell lines and primary breast
cancers suggests that 90% of invasive ductal carcinomas
express PLU-1 (Barrett et al., 2002; Lu et al., 1999). To ex-
amine the role of PLU-1 in the proliferative capacity of
MCF-7 cells, a stable shRNA knockdown strategy was uti-
lized to reduce PLU-1 expression. Two knockdown clones
(KD1 and KD2) that target two different regions of PLU-1
mRNA were generated. Both knockdown lines showed
significant reduction in the levels of PLU-1 expression as
accessed by western blot analysis (Figure 4A) and real-
time RT-PCR (Figure 4H). Although PLU-1 has several
related homologs (Figure 1A), knockdown of PLU-1 does
not affect the expression of a closely related family mem-
ber, JARID1A/RBP2 (Figure S2), indicating the knock-
down is specific.
To examine whether reduced PLU-1 levels affect
MCF-7 cell proliferation, the growth rate of the knockdown
cell lines was compared to the control cell lines derived
from transfection of empty vectors (Figure 4B). Both
PLU-1 knockdown cell lines exhibited a slower growth
rate when compared to that of the control cell lines, indi-
cating that PLU-1 expression is directly related to the pro-
liferative capacity of MCF-7 cells. Consistent with this804 Molecular Cell 25, 801–812, March 23, 2007 ª2007 Elseviobservation, anchorage-independent soft-agar colony-
formation analysis demonstrates that PLU-1 knockdown
inhibits colony formation (Figure 4C). Because reduction
of PLU-1 levels in MCF-7 cells decreased their colony-
forming capacity, PLU-1 might contribute to the trans-
formed phenotype of MCF-7. To understand how PLU-1
knockdown leads to the cell-proliferation defects, we per-
formed apoptosis and cell-cycle analysis. No significant
difference in the ratio of apoptotic cells is observed
when the knockdown cells are compared with control
cells (Figure 4D). FACS analysis demonstrates that knock-
down of PLU-1 reduces the S phase cell population, from
41% to 34%, with a concomitant increase in the G1 cell
population from 45% to 53%, whereas the G2/M cell pop-
ulation remained essentially unchanged (Figure 4E). These
data suggest a G1 promoting activity of PLU-1. Consistent
with this finding, 45% of control cells have entered the S
phase at 24 hr, but only 34% of PLU-1 knockdown cells
have reached S phase at the same time after addition of
serum to serum-starved MCF-7 cells (Figure 4F). Based
on these results, we conclude that PLU-1 positively regu-
lates the cell cycle by facilitating the G1 to S transition.
PLU-1 Represses Negative Regulators
of Cell Growth
PLU-1 functions as transcriptional repressor when teth-
ered to an artificial reporter gene in transient transfectioner Inc.
Molecular Cell
PLU-1-Mediated H3K4 Demethylation in Breast CancerFigure 3. Multiple Domains in PLU-1 Contribute to Its Histone Demethylase Activity
(A) Schematic representation of wild-type and mutant PLU-1 proteins with their localization pattern and demethylase activity against H3K4me3
indicated right. For the demethylase activity, a plus sign (+) represents active and a minus sign () represents inactive.
(B–F) Various mutant PLU-1-MYC proteins were expressed in U2OS cells, and histone modification levels were analyzed by immunofluorescent stain-
ing with H3K4me3-specific antibodies. Arrows indicate PLU-1-transfected cells. Only the C-terminal portion of PLU-1 is dispensable for its H3K4me3
demethylase activity (B). Shown are representative fields for each transfection.assays, suggesting that PLU-1 may function to repress
genes related to proliferation of MCF-7 cells (Tan et al.,
2003). To examine this possibility, the gene expression
levels of a series of tumor suppressor genes previously
linked to breast cancer were examined in PLU-1 knock-
down cell lines. Because the sole JARID1 homolog in
Drosophila, Lid, is a trithorax group protein (Gildea et al.,
2000), we also analyzed the effect of PLU-1 knockdown
on the expression of some HOXA genes. Of the genes an-
alyzed, an increase in expression of several genes, includ-
ing 14-3-3s, BRCA1, CAV1, and HOXA5, was observed in
knockdown cell lines as accessed by conventional and
real-time RT-PCR (Figures 4G and 4H). Upregulation of
these genes was observed in both knockdown cell lines,
verifying that expression differences are caused by
PLU-1 knockdown. None of the candidate genes exam-
ined in PLU-1 knockdown cells showed reduced gene
expression, in support of the observation that PLU-1 is
a transcriptional repressor (Tan et al., 2003).
Knockdown of PLU-1 Results in Increased
H3K4me3 Levels at Target Genes
To determine if genes affected in knockdown lines are di-
rect targets of PLU-1, chromatin immunoprecipitation
(ChIP) was utilized to access association of PLU-1 withMolecuthe 14-3-3s, CAV1, HOXA5, and BRCA1 genes (Figures
5A, 5C, and 5E). Toward this end, four regions in each
gene that are highly conserved between human and
mouse were chosen for PLU-1 ChIP analysis. This analysis
demonstrated that PLU-1 was efficiently immunoprecipi-
tated at three of the four genes analyzed (Figures 5A,
5C, and 5E), demonstrating that PLU-1 is directly associ-
ated with these target genes. However, no binding of
PLU-1 to the 14-3-3s gene was detected (data not shown),
indicating that PLU-1 may regulate 14-3-3s expression
indirectly. It is interesting to note, of the three target genes
identified, PLU-1 bound to each of them in a region close
to the transcriptional start site, suggesting its repressive
effects may be related to transcriptional initiation.
To determine the consequence of PLU-1 binding, H3K4
methylation levels were analyzed at PLU-1-associated re-
gions in control and PLU-1 KD cells (Figures 5B, 5D, and
5F). In PLU-1 KD cells, all three target genes showed re-
duced levels of PLU-1 occupancy, which correlated with
increases in H3K4me3 levels, but the H3K4me2 and
me1 levels were unaffected. The effects on H3K4me3
methylation were specific to PLU-1-associated regions,
as portions of the gene not associated with PLU-1 showed
no change in H3K4me3 levels in response to PLU-1 KD.
Surprisingly, the levels of H3K4me2 and me1 were notlar Cell 25, 801–812, March 23, 2007 ª2007 Elsevier Inc. 805
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PLU-1-Mediated H3K4 Demethylation in Breast CancerFigure 4. PLU-1 Knockdown Impairs Cell Proliferation through G1 Arrest and Upregulation of Certain Tumor Suppressor Genes
(A) Two PLU-1 shRNA knockdown cell lines (KD1 and KD2) were generated by stable transfection of MCF-7 cells. Both cell lines show greater than
90% knockdown at the protein level as accessed by western blot analysis for PLU-1 (top panel). a-tubulin serves as a loading control (bottom panel).
(B) The growth rate of PLU-1 knockdown cell lines was compared to control cell lines over a 5 day period. PLU-1 knockdown lines showed a marked
decrease in proliferation compared to the control cells. Shown is the average of three independent experiments with error bars. An asterisk (*) indi-
cates both KD lines are statistically significant (p < 0.05) when compared with Ctrl1.
(C) Wild-type and PLU-1 knockdown MCF-7 cells were assayed for their ability to proliferate and form colonies in soft agar. Shown are representative
fields from control (Ctrl) and knockdown (KD1 and KD2) cells after 21 days of culture. Scale bar, 0.2 mm.
(D) PLU-1 knockdown does not induce apoptosis in MCF-7 cells. Apoptotic cells were detected by flow cytometry using FITC-conjugated Annexin
V staining. Shown is the average of three independent experiments with error bars.
(E and F) Flow-cytometry analysis of cell-cycle distribution. Asynchronized (E) or serum-starvation synchronized (F) MCF-7 cells were stained with PI
and analyzed by flow cytometry. Shown are representative results from three independent experiments.
(G) The transcript levels of several breast cancer-associated genes and Hox genes were analyzed in control and KD cell lines by using RT-PCR. Sev-
eral genes implicated in breast cancer cell proliferation were specifically upregulated in knockdown cells, including 14-3-3s, BRCA1, CAV1, and
HOXA5.
(H) Genes showing reactivation by conventional RT-PCR were analyzed by real-time RT-PCR to quantify fold increase in gene expression compared
to control lines.806 Molecular Cell 25, 801–812, March 23, 2007 ª2007 Elsevier Inc.
Molecular Cell
PLU-1-Mediated H3K4 Demethylation in Breast CancerFigure 5. PLU-1 Directly Represses CAV1, HOXA5, and BRCA1 Expression by Controlling Their H3K4me3 Levels
(A, C, and E) Four regions (labeled [a]–[d]) of the CAV1 (A), HOXA5 (C), and BRCA1 (E) genes were analyzed for PLU-1 association by ChIP. PLU-1
specifically associates with regions close to sites of transcriptional initiation.
(B, D, and F) H3K4 methylation levels at PLU-1 binding regions were analyzed in control and PLU-1 KD cells by ChIP. Primer pairs corresponding to
PLU-1-bound regions are depicted in the left-hand panels, and control regions not bound by PLU-1 are depicted in the right-hand panels. In each
case, PLU-1KD cell lines displayed reduced PLU-1 binding to target genes (lane 3) and increases in H3K4me3 (lane 4) consistent with its role in
H3K4 demethylation.significantly affected in the KD cell lines, suggesting that
although PLU-1 can target all three H3K4 methylation
states (Figure 2) it preferentially regulates the level of
H3K4me3 at target genes in MCF-7 cells. In contrast to
the gene-specific effect described above, knockdown of
PLU-1 does not affect global H3K4 methylation levels
(Figure S3), likely due to the existence of multiple H3K4
demethylases in MCF-7 cells.
PLU-1-Mediated H3K4 Demethylation Is Required
for Repression of Target Genes
To examine whether PLU-1 relies on its H3K4 demethy-
lase activity for transcriptional repression, wild-type and
catalytically deficient PLU-1 were expressed in 293T cells
and the expression of PLU-1 target genes was analyzed
by real-time RT-PCR (Figure 6A). Expression of wild-
type protein had little effect on gene expression with target
genes remaining repressed. Expression of a catalytically
deficient mutant of PLU-1 resulted in increased target-
gene expression (Figure 6A), demonstrating that histone
demethylation is directly linked to PLU-1-mediated tran-Molecscriptional repression. To analyze whether the exogenous
PLU-1 binds directly to its endogenous target genes, we
chose to analyze PLU-1-Myc occupancy on HOXA5
gene by ChIP, which revealed a similar binding pattern
to that of endogenous PLU-1 (Figures 6B and 5C). This
suggests that the catalytically deficient PLU-1 mutant
may alleviate repression by acting in a dominant-negative
fashion to inhibit active H3K4 demethylation. To directly
examine whether the catalytically deficient PLU-1 mutant
functions to alleviate H3K4me3 demethylation, the levels
of H3K4 methylation at the PLU-1 binding site of the
HOXA5 gene were analyzed in cells expressing wild-type
or mutant PLU-1 (Figure 6C). Expression of the wild-type
protein resulted in a reduction of H3K4me3, indicating
that an increased level of PLU-1 potentiated H3K4me3
demethylation. In cells expressing catalytically deficient
PLU-1, there was an increase in H3K4me3 methylation,
suggesting a key function of PLU-1 in transcriptional reg-
ulation of target genes is to antagonize H3K4 methylation
(Figure 6C). Together, these data provide strong evidence
that PLU-1 functions to maintain breast cancer cellular Cell 25, 801–812, March 23, 2007 ª2007 Elsevier Inc. 807
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PLU-1-Mediated H3K4 Demethylation in Breast CancerFigure 6. PLU-1-Mediated Repression Relies on H3K4 Demethylation
(A) PLU-1-MYC (WT) or PLU-1-MYC with a mutation in the catalytic domain (MT) was transiently expressed in 293T cells as indicated by western blot
with Myc-specific antibodies (top panel). The expression levels of CAV-1, BRCA1, and HOXA5 were analyzed in cells expressing wild-type (WT) or
mutant (MT) PLU-1 by real-time RT-PCR (bottom panel). Expression of catalytically deficient PLU-1 (MT) caused reactivation of PLU-1 target genes.
(B) Exogenous PLU-1-MYC (WT or MT) binds to target genes at the same sites as endogenous PLU-1 as indicated by ChIP analysis using Myc
antibodies.
(C) The levels of H3K4 methylation at the HOXA5 gene were analyzed by ChIP in 293T cells expressing wild-type or mutant PLU-1. At the PLU-1 bind-
ing site in the HOXA5 gene (left panel), the levels of H3K4me3 decrease in cells expressing wild-type protein (lane 2) and increased in cells expressing
mutant protein (lane 3). In contrast, at a region without PLU-1 binding, overexpression of PLU-1, wild-type or mutant, exhibited no effect on H3K4me3
levels.proliferation through a transcriptional repression program
relying on its histone demethylase activity.
PLU-1 Promotes Cancer Cell Proliferation
in a Syngeneic Mouse Mammary Tumor Model
We have demonstrated in the human breast cancer cell
MCF-7 that PLU-1 positively regulates cell proliferation
by facilitating G1/S transition (Figure 4). To assess the
role of PLU-1 in breast cancer in vivo, we utilized a synge-
neic mouse mammary tumor model (Heppner et al., 2000).
It has been reported that the 4T1 cells, originally derived
from a spontaneous mouse mammary carcinoma in the
BALB/c strain (Aslakson and Miller, 1992), can mimic sev-
eral aspects of the human mammary carcinoma (Pulaski
et al., 2000). Recently, the role of STAT3 in breast cancer
growth and metastasis has been studied by injection of
the 4T1 cells, with or without knocking down of STAT3,
into BALB/c mice (Ling and Arlinghaus, 2005). To explore
the role of mouse Plu-1 in mammary tumorigenesis in this
model, we generated two stable knockdown 4T1 clones
(KD1 and KD2) that target different regions of Plu-1
mRNA. Western blot analysis indicates that both knock-
down lines showed at least 50% reduction in the levels
of Plu-1 expression (Figure 7A). Similar to the observations
in the MCF-7 cell line (Figure 4B), knockdown of Plu-1 re-
duced 4T1 cell proliferation (Figure 7B). To determine
whether Plu-1 levels affect 4T1 cell proliferation in vivo,
equal numbers of mock and Plu-1 knockdown 4T1 cells
were implanted into the mammary fat pad of syngeneic
immunocompetent BALB/c mice and the effect of Plu-1
knockdown on tumor growth was analyzed. Results
shown in Figures 7C and 7D demonstrate that knockdown808 Molecular Cell 25, 801–812, March 23, 2007 ª2007 Elsevieof Plu-1 reduced tumor cell growth. Thus, we conclude




Using a candidate approach, we have identified PLU-1 as
an H3K4 demethylase that functions both in vitro and
in vivo to remove the H3K4me3 modification state.
H3K4me3 correlates strongly with active gene expression.
In budding yeast, this modification is specifically enriched
in the 50 end of actively transcribed genes and is involved
in transcriptional initiation and elongation (Ng et al., 2003).
Upon transcriptional activation, H3K4me3 levels rapidly
increase but are swiftly lost following attenuation of tran-
scription (Zhang et al., 2005). This loss of H3K4me3 could
be explained by histone eviction or replacement, but the
identification of an H3K4me3 demethylase, which has
a single ortholog in budding yeast, provides a direct enzy-
matic mechanism by which H3K4 methylation can be rap-
idly removed and potentially contribute to transcriptional
silencing. In mammals, the dynamics of H3K4 methylation
are less well characterized, but our observations suggest
that PLU-1 can maintain the repressed state of certain
genes through H3K4 demethylation. One aspect of tran-
scriptional regulation where H3K4 demethylation could
potentially have important roles is in the regulation of in-
ducible genes whose protein product is tightly controlled
and only required in the presence of certain cellular stim-
uli. For example, during hormone-responsive gene activa-
tion, there is a rapid increase in H3K4 methylationr Inc.
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Breast Cancer Cell Proliferation In Vitro
and In Vivo
(A) Two Plu-1 shRNA knockdown cell lines
(KD1 and KD2) were generated by stable trans-
fection of 4T1 cells. Both cell lines show greater
than 50% knockdown at the protein level as as-
sessed by western blot analysis for PLU-1 (top
panel). a-tubulin serves as a loading control
(bottom panel).
(B) The growth rate of Plu-1 knockdown 4T1
cell lines (KD1 and KD2) was compared to con-
trol cell lines over a 5 day period. The growth of
Plu-1 knockdown lines was slower compared
to the control cells. Shown is the average of
three independent experiments with error
bars. An asterisk (*) indicates both KD lines
are statistically significant (p < 0.05) when com-
pared with Ctrl.
(C) The growth curve of implanted tumor cells.
Shown are the average tumor volumes with
error bars for each group (n = 6). An asterisk
(*) indicates both KD lines are statistically sig-
nificant (p < 0.05) when compared with Ctrl.
(D) Shown is a representative image of tumor-
bearing mice and their tumors at day 21 after
4T1 cell implantation. Scale bar, 10 mm.concomitant with gene activation (Dreijerink et al., 2006).
In the absence of an activating signal, transcriptional re-
pressors are recruited to these inducible genes to reset
the silenced state. It will be interesting to examine whether
PLU-1, or related H3K4 demethylases, are involved in re-
establishing the silenced state and reversing the H3K4
methylation marks during this phase of active repression.
Regulation of Breast Cancer-Related Genes
by PLU-1-Mediated H3K4 Demethylation
PLU-1 was first identified as a gene upregulated in breast
cancer cell lines (Lu et al., 1999). Initial studies character-
izing PLU-1 as a transcriptional repressor suggested its
abnormal expression in breast cancer lines may contrib-
ute to altered transcriptional profiles of breast cancer-re-
lated genes. To explore this possibility, we examined the
gene-expression profiles of several cancer-associated
genes in two independent PLU-1 knockdown cell lines
and found that BRCA-1, CAV1, 14-3-3-sigma, and
HOXA5 were specifically upregulated in the PLU-1 knock-
down cells. In addition to gene expression defects, PLU-1
knockdown cells also displayed a reduced growth rate
likely due to a defect in the G1/S transition. It is likely
that reduced proliferation in PLU-1 knockdown cells is
due to re-expression of genes normally repressed by
PLU-1, as all identified target genes have been implicated
in inhibition of cell growth. For example, exogenous
BRCA1 expression in MCF-7 cells caused substantial re-
duction in cell growth and failed to support tumor forma-
tion when injected into nude mice (Jensen et al., 1996).
Like BRCA1, exogenous expression of CAV1 in MCF-7
cells also leads to reduced cell proliferation (Fiucci et al.,Molec2002). Interestingly, exogenous expression of HOXA5
was previously shown to induce p53 expression, leading
to apoptosis in breast cancer cells (Raman et al., 2000).
In PLU-1 knockdown cells, HOXA5 is upregulated 4-fold
but p53 levels are only slightly increased in one of the
two knockdown lines. This suggests that the level of
HOXA5 upregulation in PLU-1 knockdown cells is not suf-
ficient to result in robust p53 reactivation but does not rule
out the possibility that other target genes more sensitive to
HOXA5 levels are affected. Together, these observations
indicate that PLU-1 positively regulates cell proliferation
by repressing the expression of cell-growth inhibitors.
Recent studies indicate that altered expression profiles
of histone methyltransferase enzymes or abnormal target-
ing of these enzymes contributes to malignancy (Hama-
moto et al., 2004; Jones and Baylin, 2007; Okada et al.,
2005, 2006). This is exemplified by the oncogenic MLL-
AF10 fusion protein, which aberrantly targets DOT1L-me-
diated H3K79 methylation to the HOXA9 gene, leading to
increased gene expression and leukemogenesis (Okada
et al., 2005). Based on the prevalence of altered histone
methylation profiles in cancer, it seems likely that histone
demethylases will also be exploited to circumvent normal
cellular homeostasis. In agreement with this hypothesis,
MCF-7 breast cancer lines utilize the H3K4 demethylase
activity of PLU-1 to repress genes normally involved in
control of cell growth. All PLU-1 target genes analyzed
show a direct correlation between expression level and
the capacity of PLU-1 to regulate promoter-associated
H3K4me3 levels. It will be interesting to determine, using
global gene expression profiling techniques, whether
PLU-1 has a more extensive role in regulating transcriptionular Cell 25, 801–812, March 23, 2007 ª2007 Elsevier Inc. 809
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cancer cells, we have also demonstrated a role for Plu-1 in
murine mammary tumor by using the mouse 4T1/BALB/c
immunocompetent tumor model system. If PLU-1 func-
tions as a pivotal regulator of breast cancer proliferation,
this could be a potentially important therapeutic target.
Because PLU-1 appears to mediate its repressive effect
through H3K4 demethylation, compounds targeting its
demethylase function may act to inhibit breast cancer
cell growth.
Regulation of H3K4 Methylation by JARID1
Family Members
PLU-1 is a member of the JARID1 family of proteins that
consists of four members in mouse and human. The other
three members of the JARID1 family (JARID1A/RBP2,
JARID1C/SMCX, and JARID1D/SMCY) are highly similar
to PLU-1, and all have conserved residues within the pre-
dicted cofactor binding sites, suggesting that they will
function as H3K4 demethylases (Klose et al., 2006a).
The sequence similarity and domain architecture conser-
vation between JARID1 family members suggests that
some functional redundancy between these proteins is
likely to exist, but experimental evidence indicates that in-
dividual members also have unique functional properties
and divergent expression profiles.
JARID1A/RBP2 was the first characterized member of
the JARID1 family and was originally identified by its phys-
ical interaction with the tumor suppressor protein pRB (De-
feo-Jones et al., 1991). The effect of RBP2 on transcription
is context dependent and can function as either a tran-
scriptional repressor or an activator, depending on the
specific target gene analyzed (Benevolenskaya et al.,
2005; Chan and Hong, 2001). RBP2 is ubiquitously ex-
pressed (Fattaey et al., 1993), and RBP2-null mice display
defects in haematopoiesis that appear to be related to al-
tered expression profiles of certain cytokine genes (Klose
et al., 2007). At the molecular level, RBP2 acts as a potent
gene-specific H3K4 demethylase and directly represses
some of the misregulated cytokine genes identified in
RBP2/ cells (Klose et al., 2007). PLU-1 displays the
most restricted expression pattern of all the JARID1 family
members, showing high levels of expression in the testis
and only low levels of expression in other tissues (Lu
et al., 1999). Although it is clear that PLU-1 contributes to
breast cancer proliferation, the normal function of PLU-1
in the testis remains unknown. The restricted expression
pattern does, however, suggest that PLU-1-mediated
H3K4 demethylation may play an important role in male
gamete development. Very little is known about the molec-
ular function of JARID1C/SMCX, with the exception that it
escapes X inactivation (Wu et al., 1994) and is mutated in
X-linked mental retardation (Jensen et al., 2005). Whether
SMCX is enzymatically active remains to be determined,
but high levels of conservation within the JmjC domain
suggest it will likely to be an active demethylase with activ-
ity against methylated H3K4. SMCY is a broadly expressed
Y chromosome-encoded gene that has been identified as810 Molecular Cell 25, 801–812, March 23, 2007 ª2007 Elsevia male histocompatibility antigen (Wang et al., 1995). It will
be interesting to determine the normal nuclear function of
SMCY and determine whether its H3K4 demethylase
activity plays a role in sex-specific gene regulation.
The revelation that JARID1 proteins are H3K4 demethy-
lases has demonstrated that H3K4me3 is a reversible epi-
genetic mark. This discovery provides a basis for more
mechanistic studies into H3K4me3 dynamics during regu-
lation of gene expression and indicates that active removal
of H3K4 methylation may contribute to cancer. Remark-
ably, despite the sequence similarity of the JmjC domain
between characterized histone demethylases, individual
enzymes appear to have very distinct specificity with
regard to both methylation site and state. Although the re-
cently solved structure of the JHDM3A/JMJC2A JmjC
domain indicates how the catalytic core of these enzymes
is arranged, the specificity determinants within each pro-
tein remain unknown (Chen et al., 2006). Further structural
analysis using enzyme/substrate complexes will hopefully
provide information regarding the substrate determinants
for these unique enzymes and perhaps provide information
for the rational design of histone demethylase inhibitors.
EXPERIMENTAL PROCEDURES
Histone Demethylase Assay
The histone demethylase assay was performed essentially as previ-
ously described (Tsukada et al., 2006). Briefly, various 3H-labeled his-
tone substrates or histone peptides were incubated with recombinant
PLU-1 in histone demethylation buffer (50 mM HEPES-KOH [pH 7.5],
70 mM Fe[NH4]2[SO4]2, 1 mM a-ketoglutarate, and 2 mM ascorbate)
at 37C for 1–3 hr. Demethylation was analyzed by the NASH method
and mass spectrometry. For detection of 3H-labeled formaldehyde,
a modified NASH method (Kleeberg and Klinger, 1982) was used. After
TCA precipitation, an equal volume of NASH reagent (3.89 M ammo-
nium acetate, 0.1 M acetic acid, and 0.2% 2,4-pentanedione) was
added into the supernatant and the mixtures were incubated at 37C
for 50 min before extraction with equal volume of 1-pentanol. The
extracted radioactivity was measured by scintillation counting. For
detection of demethylation with peptide substrates, peptides in the
reaction mixtures were desalted on a RP microtip and analyzed by
MALDI-TOF as described previously (Tsukada et al., 2006).
Immunostaining
U2OS cells were plated onto glass coverslips in a 12-well plate and cul-
tured for 1 day. Cells were transiently transfected with plasmids by Fu-
Gene6. Two days after transfection, cells were washed with PBS and
fixed in 4% paraformaldehyde for 10 min. The cells were then washed
three times with cold PBS and permeabilized for 5 min with cold PBS
containing 0.2% Triton X-100. Permeabilized cells were then washed
three times with blocking buffer (1% bovine serum albumin in PBS)
and blocked for 30 min before incubation with primary antibodies for
1 hr in a humidified chamber. After three consecutive 5 min washes
with PBS, cells were incubated with secondary antibodies for 1 hr be-
fore being washed with PBS and stained with 4,6-diamidino-2-phenyl-
indole dihydrochloride (DAPI) in PBS. Cells were washed twice with
PBS and then mounted in fluorescent mounting medium (Dako) before
being viewed under a Zeiss immunofluorescence microscope.
Generation of Stable PLU-1/Plu-1 Knockdown Cell Lines
and Cell-Growth Analyses
MCF-7 and 4T1 cells were cultured in DMEM media supplied with 10%
FBS. To generate stable PLU-1/Plu-1 knockdown cell lines, siRNAer Inc.
Molecular Cell
PLU-1-Mediated H3K4 Demethylation in Breast Cancervectors were transfected into MCF-7 or 4T1 cells. Stable transfectants
were selected in the presence of 1 mg/ml (MCF-7) or 3 mg/ml (4T1) pu-
romycin (Gibco). Cells derived from these transfectants were used for
western blotting, real-time PCR, and ChIP analysis. For cell-growth
analyses, 3 3 104 cells were seeded in 12-well plates. After 24, 48,
72, 96, and 120 hr in culture, cells were trypsinized, collected in tripli-
cate, and counted by trypan-blue staining.
Cell-Cycle and Apoptosis Analysis
MCF-7 cells were synchronized by serum starvation for 24 hr and were
released by culturing in DMEM media with 10% FBS for 24 hr. After ex-
posing to 10 mM BrdU for 30 min, cells were harvested and fixed in
70% ethanol. Cells were then washed with PBS, resuspended, and in-
cubated with 4N HCL and 0.5% Triton X-100 for 30 min at room tem-
perature. After washing with PBS, cells were neutralized with 0.1 M so-
dium borate before being labeled with FITC-conjugated BrdU antibody
(BD Biosciences) and incubated with 50 mg/ml propidium iodide
(Sigma) containing 125 mg/ml RNase (Calbiochem). Cells were then fil-
trated through a nylon mesh (95 mm pore size), and a total of 20,000
stained nuclei were analyzed in a Cyan Flow Cytometer (BD Biosci-
ences). For apoptosis analysis, MCF-7 cells were serum starved for
24 hr and released to DMEM media containing 10% FBS for 24 hr.
Cells were harvested and washed with PBS, and then subjected to se-
quential staining with Annexin V-FITC and propidium iodide according
to the manufacturer’s protocol (BD Biosciences) before being ana-
lyzed by Cyan Flow Cytometer.
Soft-Agar Colony-Formation Assays
MCF-7 cells suspended in 0.35% agar (15,000 cells/dish) were layered
on top of 1 ml of solidified agar (0.6%) in a 35 mm dish in the presence
of 100 nM 17b-estradiol (Sigma). DMEM growth medium with a final
concentration of 10% FBS was included in both layers. After 21 days
of incubation, colonies were counted and photographed at 103 mag-
nification. Experiments were carried out in triplicate.
Animals, 4T1 Cell Culture, and Implantation
All BALB/c mice were purchased from The Jackson Laboratories (Bar
Harbor, ME, USA). All procedures involving experimental animals were
performed in accordance with protocols approved by the Institutional
Animal Care and Use Committee (IACUC). The 4T1 cell line was pur-
chased from the American Type Culture Collection (Manassas, VA,
USA) and maintained in DMEM media with 10% FBS. For tumor cell
implantation, 1 3 106 4T1 cells were injected into mammary fat pad
of BALB/c virgin female mice (six mice were injected for each treat-
ment). The tumor size was measured, and the volume was calculated
as (length [mm] 3 width [mm]2) / 2.
Statistical Analysis
The data are expressed as means ± SEM. Statistical data of cell growth
or tumor volume are analyzed by using a two-tailed Student’s t test.
Values of p < 0.05 were considered to be statistically significant.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, three figures, and two tables and can be
found with this article online at http://www.molecule.org/cgi/content/
full/25/6/801/DC1/.
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